Nov 18, 2022 Early signal of activity from a phase 2 study of ST101, a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ), in recurrent glioblastoma (GBM)
Nov 10, 2022 ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responses
Oct 27, 2022 Efficacy signals, long-term exposure and safety data from a phase 1-2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients with refractory solid tumors
Jun 3, 2022 Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors
Apr 11, 2022 Characterizing the PK/PD relationship of C/EBPβ antagonist peptide ST101 in a mouse orthotopic breast cancer model
Sep 16, 2021 Efficacy, safety, pharmacokinetic and pharmacodynamic data from phase 1 dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients with advanced and metastatic solid tumors
Apr 9, 2021 Tumor uptake and dose-proportional PK of ST101 - a peptide antagonist of C/EBPβ – in patients with advanced unresectable and metastatic solid tumors
